Handem Sara, Ferreira Bárbara, Valente Carina, Sá-Leão Raquel
Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa (ITQB NOVA), Avenida da República, Oeiras, 2780-157, Portugal.
Polytechnic University of Castelo Branco, Castelo Branco, Portugal.
BMC Genomics. 2025 Jul 1;26(1):577. doi: 10.1186/s12864-025-11756-x.
(pneumococcus), , and are closely related bacteria that colonize the human upper respiratory tract. While pneumococcus is a leading cause of global morbidity and mortality, and are generally considered commensals, rarely causing disease in immunocompetent hosts. Here, we characterized the genomes of seven commensal streptococcal strains ( A22 and B22–G22) identified as potential biotherapeutics due to their bacteriocin-mediated antipneumococcal activity.
Comparative genomic analyses revealed key differences between these commensals and pneumococci. Commensal strains encode diverse adhesin-like proteins, absent in pneumococci, and lack key virulence factors such as pilus islets and pneumococcal surface proteins. They also possess extensive restriction-modification and type II toxin-antitoxin systems, alongside novel prophages, suggesting roles in genetic stability and phage defense. Metabolic adaptations in commensals indicate a “cheater” strategy, relying on extracellular metabolites from other microorganisms, particularly in the nutrient-scarce nasopharynx. Additionally, commensal strains exhibit distinct teichoic acid compositions, with galactose-rich lipoteichoic acids potentially enhancing niche adaptation. Capsular diversity was also observed, with some strains encoding unique polysaccharides. These findings highlight genomic features that likely enhance commensal colonization and survival in the upper respiratory tract, while distinguishing them from pneumococci.
This study highlights the genomic characteristics of the seven commensal streptococcal strains with broad anti-pneumococcal activity recently described and provides insights into species-specific traits that could inform targeted strategies for pneumococcal control.
The online version contains supplementary material available at 10.1186/s12864-025-11756-x.
肺炎链球菌、缓症链球菌和口腔链球菌是定植于人类上呼吸道的密切相关细菌。虽然肺炎链球菌是全球发病和死亡的主要原因,但缓症链球菌和口腔链球菌通常被认为是共生菌,在免疫功能正常的宿主中很少引起疾病。在此,我们对七株共生链球菌菌株(缓症链球菌A22和口腔链球菌B22 - G22)的基因组进行了表征,这些菌株因其细菌素介导的抗肺炎链球菌活性而被鉴定为潜在的生物治疗剂。
比较基因组分析揭示了这些共生菌与肺炎链球菌之间的关键差异。共生菌株编码肺炎链球菌中不存在的多种黏附素样蛋白,并且缺乏关键毒力因子,如菌毛岛和肺炎链球菌表面蛋白。它们还拥有广泛的限制修饰和II型毒素 - 抗毒素系统,以及新型原噬菌体,表明在遗传稳定性和噬菌体防御中发挥作用。共生菌的代谢适应性表明其采用“欺骗”策略,依赖于其他微生物的细胞外代谢产物,特别是在营养稀缺的鼻咽部。此外,共生菌株表现出独特的磷壁酸组成,富含半乳糖的脂磷壁酸可能增强生态位适应性。还观察到荚膜多样性,一些菌株编码独特的多糖。这些发现突出了可能增强上呼吸道共生定植和存活的基因组特征,同时将它们与肺炎链球菌区分开来。
本研究突出了最近描述的具有广泛抗肺炎链球菌活性的七株共生链球菌菌株的基因组特征,并提供了物种特异性特征的见解,可为肺炎链球菌控制的靶向策略提供信息。
在线版本包含可在10.1186/s12864 - 025 - 11756 - x获取的补充材料。